SE435374B - Terapeutiskt aktiva derivat av 4-(2-hydroxi-3-amino-propoxi)-indol, deras framstellning och anvendning. - Google Patents
Terapeutiskt aktiva derivat av 4-(2-hydroxi-3-amino-propoxi)-indol, deras framstellning och anvendning.Info
- Publication number
- SE435374B SE435374B SE7807753A SE7807753A SE435374B SE 435374 B SE435374 B SE 435374B SE 7807753 A SE7807753 A SE 7807753A SE 7807753 A SE7807753 A SE 7807753A SE 435374 B SE435374 B SE 435374B
- Authority
- SE
- Sweden
- Prior art keywords
- carbon atoms
- compounds
- halogen
- given above
- formula
- Prior art date
Links
- -1 2-HYDROXY-3-AMINO-PROPOXY Chemical class 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 5
- 150000002475 indoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 58
- 125000004432 carbon atom Chemical group C* 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 29
- 150000002367 halogens Chemical class 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 150000002431 hydrogen Chemical group 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000002503 metabolic effect Effects 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000001800 adrenalinergic effect Effects 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000003340 mental effect Effects 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 206010047139 Vasoconstriction Diseases 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 2
- 230000008991 intestinal motility Effects 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 230000025033 vasoconstriction Effects 0.000 claims description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000001769 paralizing effect Effects 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000000460 chlorine Substances 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- IMLAIXAZMVDRGA-UHFFFAOYSA-N 2-phenoxyethanamine Chemical compound NCCOC1=CC=CC=C1 IMLAIXAZMVDRGA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-M malonate(1-) Chemical compound OC(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021333 Ileus paralytic Diseases 0.000 description 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 201000007620 paralytic ileus Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH906577 | 1977-07-21 | ||
| CH907377 | 1977-07-21 | ||
| CH907077 | 1977-07-21 | ||
| CH907777A CH632246A5 (en) | 1977-07-21 | 1977-07-21 | Process for preparing novel 3-aminopropoxyindoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7807753L SE7807753L (sv) | 1979-01-22 |
| SE435374B true SE435374B (sv) | 1984-09-24 |
Family
ID=27429188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7807753A SE435374B (sv) | 1977-07-21 | 1978-07-12 | Terapeutiskt aktiva derivat av 4-(2-hydroxi-3-amino-propoxi)-indol, deras framstellning och anvendning. |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS5422364A (it) |
| AU (1) | AU523105B2 (it) |
| BE (1) | BE869133A (it) |
| CA (1) | CA1098909A (it) |
| DE (1) | DE2830211A1 (it) |
| DK (1) | DK312878A (it) |
| ES (1) | ES471863A1 (it) |
| FI (1) | FI782229A7 (it) |
| FR (1) | FR2398058A1 (it) |
| GB (1) | GB2001971B (it) |
| IE (1) | IE47131B1 (it) |
| IL (1) | IL55170A (it) |
| IT (1) | IT1105092B (it) |
| NL (1) | NL7807626A (it) |
| NZ (1) | NZ187909A (it) |
| PT (1) | PT68317A (it) |
| SE (1) | SE435374B (it) |
| SU (1) | SU843740A3 (it) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2905877A1 (de) * | 1979-02-16 | 1980-08-28 | Boehringer Mannheim Gmbh | Neue aminopropanolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| EP0025111B1 (en) * | 1979-08-10 | 1984-07-25 | Sandoz Ag | 3-aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them |
| DE3029980A1 (de) * | 1980-08-08 | 1982-03-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | Indolderivate und verfahren zu ihrer herstellung |
| DE3030047A1 (de) * | 1980-08-08 | 1982-03-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE3131146A1 (de) * | 1981-08-06 | 1983-02-24 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue heteroaryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| ZA967892B (en) * | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| US6818660B2 (en) | 1996-04-09 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
| DE69733649T2 (de) | 1996-04-09 | 2006-05-18 | NPS Pharmaceuticals, Inc., Salt Lake City | Calcylitische verbindungen |
| ES2171839T3 (es) * | 1996-09-05 | 2002-09-16 | Lilly Co Eli | Analogos de carbazol como agonistas adrenergicos selectivos de beta3. |
| TW483881B (en) | 1996-12-03 | 2002-04-21 | Nps Pharma Inc | Calcilytic compounds |
| US7202261B2 (en) | 1996-12-03 | 2007-04-10 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
| WO2001036412A1 (en) * | 1999-11-15 | 2001-05-25 | Eli Lilly And Company | Process for the preparation of aryloxy propanolamines |
| WO2017197324A1 (en) * | 2016-05-13 | 2017-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Adrenergic receptor modulating compounds and methods of using the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1547056A (fr) * | 1966-12-13 | 1968-11-22 | Sandoz Sa | Dérivés de l'indole et leur préparation |
| FR2019185A1 (en) * | 1968-09-30 | 1970-06-26 | Sandoz Sa | 4-(2-hydroxy-3-amino-propoxy)-indole-2-carboxy- - lic acids and esters and 2-hydroxymethylindoles as beta |
| US3699123A (en) * | 1970-03-24 | 1972-10-17 | Sandoz Ltd | 4-(3-amino-2-hydroxy-propoxy) indole derivatives |
| DE2508251C2 (de) * | 1975-02-26 | 1983-12-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Derivate des Indols, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel |
| US4076829A (en) * | 1974-11-16 | 1978-02-28 | Boehringer Mannheim Gmbh | Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases |
| DE2633839A1 (de) * | 1975-08-07 | 1977-02-24 | Sandoz Ag | Neue 4-aminopropoxyindolderivate, ihre herstellung und verwendung |
| DE2635209C2 (de) * | 1975-08-15 | 1983-01-27 | Sandoz-Patent-GmbH, 7850 Lörrach | 4-(2-Benzoyloxy-3-tert.butylamino-propoxy)-2-methylindol, dessen (S)-Enantiomeres, deren Säureadditionssalze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Heilmittel |
-
1978
- 1978-07-10 DE DE19782830211 patent/DE2830211A1/de not_active Ceased
- 1978-07-12 FI FI782229A patent/FI782229A7/fi not_active Application Discontinuation
- 1978-07-12 DK DK312878A patent/DK312878A/da not_active Application Discontinuation
- 1978-07-12 SE SE7807753A patent/SE435374B/sv unknown
- 1978-07-14 IT IT50299/78A patent/IT1105092B/it active
- 1978-07-17 NL NL7807626A patent/NL7807626A/xx not_active Application Discontinuation
- 1978-07-19 AU AU38182/78A patent/AU523105B2/en not_active Expired
- 1978-07-19 ES ES471863A patent/ES471863A1/es not_active Expired
- 1978-07-19 GB GB7830345A patent/GB2001971B/en not_active Expired
- 1978-07-19 IE IE1448/78A patent/IE47131B1/en unknown
- 1978-07-19 BE BE189392A patent/BE869133A/xx not_active IP Right Cessation
- 1978-07-19 PT PT68317A patent/PT68317A/pt unknown
- 1978-07-19 IL IL55170A patent/IL55170A/xx unknown
- 1978-07-19 SU SU782639449A patent/SU843740A3/ru active
- 1978-07-19 NZ NZ187909A patent/NZ187909A/xx unknown
- 1978-07-20 JP JP8781878A patent/JPS5422364A/ja active Pending
- 1978-07-20 CA CA307,768A patent/CA1098909A/en not_active Expired
- 1978-07-21 FR FR7821679A patent/FR2398058A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ES471863A1 (es) | 1979-10-01 |
| NL7807626A (nl) | 1979-01-23 |
| IE781448L (en) | 1979-01-21 |
| JPS5422364A (en) | 1979-02-20 |
| NZ187909A (en) | 1981-04-24 |
| GB2001971A (en) | 1979-02-14 |
| IL55170A0 (en) | 1978-09-29 |
| BE869133A (fr) | 1979-01-19 |
| IE47131B1 (en) | 1983-12-28 |
| AU3818278A (en) | 1980-01-24 |
| IT1105092B (it) | 1985-10-28 |
| AU523105B2 (en) | 1982-07-15 |
| SU843740A3 (ru) | 1981-06-30 |
| GB2001971B (en) | 1982-02-10 |
| IL55170A (en) | 1982-07-30 |
| IT7850299A0 (it) | 1978-07-14 |
| FR2398058A1 (fr) | 1979-02-16 |
| FI782229A7 (fi) | 1979-01-22 |
| DK312878A (da) | 1979-01-22 |
| DE2830211A1 (de) | 1979-02-01 |
| CA1098909A (en) | 1981-04-07 |
| PT68317A (fr) | 1978-08-01 |
| SE7807753L (sv) | 1979-01-22 |
| FR2398058B1 (it) | 1982-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0178874B1 (en) | Alkylsulfonamidophenylalkylamines | |
| KR100395280B1 (ko) | 신규한3환성화합물및그를함유하는의약조성물 | |
| SE435374B (sv) | Terapeutiskt aktiva derivat av 4-(2-hydroxi-3-amino-propoxi)-indol, deras framstellning och anvendning. | |
| KR910006637B1 (ko) | 트립타민 유도체의 제조방법 | |
| EP0166615A2 (en) | Improvements in or relating to benzenesulfonamido derivatives | |
| KR100199524B1 (ko) | 엔-헤테로아릴-푸린-6-아민 및 이의 제조방법 | |
| US4381398A (en) | Amino-alcohol derivatives | |
| EP0233762B1 (en) | Use of aromatic diamines for the treatment of angina pectoris, and diamines therefor | |
| WO1992005165A1 (en) | Diphenylpiperazine derivative and drug for circulatory organ containing the same | |
| US3825558A (en) | Substituted aminopropoxy-2-indolinones | |
| US4129656A (en) | Thiazolidine derivatives, salidiuretic compositions and methods of effecting salidiuresis employing them | |
| NZ229376A (en) | Aryloxysubstituted propanolamines and pharmaceutical compositions | |
| FR2660657A1 (fr) | Nouveaux derives du 3-aminochromane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
| EP0242939B1 (en) | Indole derivatives | |
| US2449638A (en) | Substituted glycinamides | |
| SE435927B (sv) | Trans-4-(2-klorofenoxi)-1-etyl-pyrrolidinol med terapeutisk verkan | |
| US4806551A (en) | N-dihydroindolylethyl-sulphonamides | |
| NO742478L (it) | ||
| NO882065L (no) | Diarylalkyl-substituerte alkylaminer, fremgangsmaate for fremstilling av dem, anvendelse av dem, saavel som legemidler som inneholder dem. | |
| US3813398A (en) | Benzenesulfonyl-semicarbazides and process for their manufacture | |
| AU738672B2 (en) | Novel antiarrhythmic compounds | |
| KR100306018B1 (ko) | 약리학적 활성을 갖는 에난티오머 | |
| US3442890A (en) | Substituted 3-benzazocin-16-ones | |
| US3808231A (en) | 4-(2-hydroxy-3-(2-alkynylamino)propoxy)indoles | |
| GB2055372A (en) | Texahydro-trans-pyridoindole neuroleptic agents |